TargeGen Initiates Phase I Clinical Trial Of Topical AMD Drug TG100801
Thu, 02 Nov 2006 08:00 AM EST
... TargeGen, Inc. has announced that the Company has initiated a single site Phase I clinical trial involving TG100801, a small molecule, topically applied multi-targeted kinase inhibitor for the treatment of macular degeneration and other debilitating diseases of the eye. Macular degeneration is the leading cause of blindness in adults. [click link for full article] ...
Related Topics
- Clinical Trials
- Age-Related Macular Degeneration
- Tarceva
- Pharmacology
- Psychopharmacology
- Benzocaine Topical
- Bevacizumab Injection
- Trastuzumab
- Drug Safety
- Prescription Drugs
- Tetracaine Topical
- Drug Side Effects
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Drug Abuse
- Drug Information
- Clinical Growth Charts
- Prescription Drug Abuse
- Prescription Drugs Abuse
- Depression

Not Signed In -


